Research ArticleClinical Investigations
Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy
Simone U. Dalm, Anieta M. Sieuwerts, Maxime P. Look, Marleen Melis, Carolien H.M. van Deurzen, John A. Foekens, Marion de Jong and John W.M. Martens
Journal of Nuclear Medicine October 2015, 56 (10) 1487-1493; DOI: https://doi.org/10.2967/jnumed.115.160739
Simone U. Dalm
1Departments of Nuclear Medicine and Radiology, Erasmus MC, Rotterdam, The Netherlands
Anieta M. Sieuwerts
2Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands; and
Maxime P. Look
2Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands; and
Marleen Melis
1Departments of Nuclear Medicine and Radiology, Erasmus MC, Rotterdam, The Netherlands
Carolien H.M. van Deurzen
3Department of Pathology, Erasmus MC, Rotterdam, The Netherlands
John A. Foekens
2Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands; and
Marion de Jong
1Departments of Nuclear Medicine and Radiology, Erasmus MC, Rotterdam, The Netherlands
John W.M. Martens
2Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands; and
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 56, Issue 10
October 1, 2015
Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy
Simone U. Dalm, Anieta M. Sieuwerts, Maxime P. Look, Marleen Melis, Carolien H.M. van Deurzen, John A. Foekens, Marion de Jong, John W.M. Martens
Journal of Nuclear Medicine Oct 2015, 56 (10) 1487-1493; DOI: 10.2967/jnumed.115.160739
Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy
Simone U. Dalm, Anieta M. Sieuwerts, Maxime P. Look, Marleen Melis, Carolien H.M. van Deurzen, John A. Foekens, Marion de Jong, John W.M. Martens
Journal of Nuclear Medicine Oct 2015, 56 (10) 1487-1493; DOI: 10.2967/jnumed.115.160739
Jump to section
Related Articles
Cited By...
- Substitution of L-Tryptophan by {alpha}-Methyl-L-Tryptophan in 177Lu-RM2 Results in 177Lu-AMTG, a High-Affinity Gastrin-Releasing Peptide Receptor Ligand with Improved In Vivo Stability
- Imaging the Distribution of Gastrin-Releasing Peptide Receptors in Cancer
- SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?
- Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors